Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROMORPHONE HYDROCHLORIDE vs MORPHINE SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Hydromorphone is a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the CNS, activating G-protein coupled receptors that inhibit adenylate cyclase, decrease c AMP production, and modulate ion channels, leading to reduced neurotransmitter release (e.g., substance P, glutamate) and hyperpolarization of neurons. This results in analgesia, sedation, and euphoria.
Agonist at mu, kappa, and delta opioid receptors in the central nervous system, mimicking endogenous endorphins. Primarily mu-receptor activation leads to analgesia by inhibiting adenylate cyclase, decreasing c AMP, and modulating ion channels (e.g., opening GIRK channels, closing voltage-gated calcium channels), reducing neurotransmitter release.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate,Off-label: acute pain (e.g., postoperative), chronic pain, breakthrough cancer pain
Moderate to severe acute pain,Severe chronic pain (e.g., cancer-related),Parenteral use for acute pain (e.g., postoperative, trauma),Off-label: dyspnea in palliative care, opioid-induced constipation antagonist in combination products
Initial: 2-4 mg orally every 3-4 hours; 1-2 mg intravenously/subcutaneously/intramuscularly every 2-4 hours. For opioid-naive patients, lower starting doses (e.g., 1-2 mg oral, 0.2-0.5 mg parenteral) are recommended.
5-10 mg intravenously every 4 hours as needed; 10-30 mg orally every 4 hours as needed; 0.1-0.2 mg/kg intramuscularly every 4 hours as needed.
Terminal elimination half-life: 2.0–3.0 hours in healthy adults; prolonged in renal impairment (up to 40 hours) and hepatic impairment; clinical context: supports dosing interval of 4–6 hours in normal renal function.
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (6-8 hours), elderly, and renal impairment (up to 15 hours).
For GFR 30-59 m L/min: administer 75% of usual dose every 4-6 hours; for GFR 10-29 m L/min: administer 50% of usual dose every 6-8 hours; for GFR <10 m L/min: administer 25% of usual dose every 8-12 hours.
GFR 30-50 m L/min: administer 75% of normal dose; GFR 10-29 m L/min: administer 50% of normal dose; GFR <10 m L/min: administer 25% of normal dose.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Hydromorphone exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Accidental ingestion, especially by children, can result in fatal overdose. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.
Hydromorphone crosses the placenta. First trimester: no clear evidence of major malformations in human studies, but opioid use in pregnancy is associated with a small increased risk of neural tube defects and congenital heart defects. Second and third trimesters: chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS). Use near term may cause neonatal respiratory depression.
First trimester: Limited data; no major malformations reported at therapeutic doses. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS) after birth. High doses near term may cause neonatal respiratory depression.
Hydromorphone is 5-7 times more potent than morphine; use equianalgesic dosing when converting. Avoid in patients with MAO inhibitor use within 14 days. Immediate-release onset is 15-30 min; peak effect at 30-60 min. For PCA, typical demand dose is 0.1-0.2 mg with 6-8 min lockout. Naloxone reversal may require repeated dosing due to hydromorphone's longer half-life. Consider renal impairment: dose adjustment needed for Cr Cl < 30 m L/min.
For opioid-naïve patients, start with immediate-release formulation; use equianalgesic dosing when converting routes (oral to parenteral ratio 3:1 for chronic dosing). Always co-prescribe a bowel regimen (e.g., senna + docusate) due to opioid-induced constipation. Monitor respiratory rate closely, especially in elderly, COPD, or sleep apnea patients. Naloxone is the reversal agent; consider prescribing naloxone for patients on high doses or concomitant benzodiazepines. Morphine is contraindicated in patients with MAOI use within 14 days.
No interactions on record
No interactions on record
Common clinical questions about HYDROMORPHONE HYDROCHLORIDE vs MORPHINE SULFATE, answered by our medical review team.
HYDROMORPHONE HYDROCHLORIDE is a Opioid Agonist that works by Hydromorphone is a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the CNS, activating G-protein coupled receptors that inhibit adenylate cyclase, decrease c AMP production, and modulate ion channels, leading to reduced neurotransmitter release (e.g., substance P, glutamate) and hyperpolarization of neurons. This results in analgesia, sedation, and euphoria.. MORPHINE SULFATE is a Opioid Agonist that works by Agonist at mu, kappa, and delta opioid receptors in the central nervous system, mimicking endogenous endorphins. Primarily mu-receptor activation leads to analgesia by inhibiting adenylate cyclase, decreasing c AMP, and modulating ion channels (e.g., opening GIRK channels, closing voltage-gated calcium channels), reducing neurotransmitter release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROMORPHONE HYDROCHLORIDE and MORPHINE SULFATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROMORPHONE HYDROCHLORIDE is: Initial: 2-4 mg orally every 3-4 hours; 1-2 mg intravenously/subcutaneously/intramuscularly every 2-4 hours. For opioid-naive patients, lower starting doses (e.g., 1-2 mg oral, 0.2-0.5 mg parenteral) are recommended.. The standard adult dose of MORPHINE SULFATE is: 5-10 mg intravenously every 4 hours as needed; 10-30 mg orally every 4 hours as needed; 0.1-0.2 mg/kg intramuscularly every 4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROMORPHONE HYDROCHLORIDE and MORPHINE SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROMORPHONE HYDROCHLORIDE is classified as Category D/X. Hydromorphone crosses the placenta. First trimester: no clear evidence of major malformations in human studies, but opioid use in pregnancy is associated with a small increased ris. MORPHINE SULFATE is classified as Category D/X. First trimester: Limited data; no major malformations reported at therapeutic doses. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Hydromorphone is extensively metabolized in the liver via glucuronidation (primarily UGT2B7) to hydromorphone-3-glucuronide, which is inactive. Minor metabolism via N-demethylation to normorphine (active) and reduction to dihydroisomorphine (active).
Primarily hepatic via glucuronidation (UGT2B7) to morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active with greater analgesic potency); minor pathways include N-demethylation to normorphine. Excretion mainly renal.
Primarily renal (approximately 90% as hydromorphone-3-glucuronide and other conjugates; <7% as unchanged hydromorphone), with a small amount biliary/fecal.
Renal: 90% (primarily as morphine-3-glucuronide and morphine-6-glucuronide, with 10% unchanged); Biliary/Fecal: 7-10%.
Approximately 20–30% bound to plasma proteins (primarily albumin).
30-35%, primarily to albumin.
1–3 L/kg; indicates extensive tissue distribution and penetration into extravascular tissues, including CNS.
3-5 L/kg; large Vd indicates extensive tissue distribution, including skeletal muscle and adipose tissue.
Oral immediate release: 30–40% (extensive first-pass metabolism); Oral extended release: 30–50% (first-pass effect; formulation-dependent); Rectal: approximately 30–40%; IM: nearly 100%; IV: 100%.
Oral: 20-40% (first-pass metabolism); IM/SC: 80-100%; Rectal: 30-50%; Intranasal: 50-60% (variable); IV: 100%.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50% and increase dosing interval; Class C: avoid use or reduce dose by 75% with extended intervals.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use with extreme caution at 25% of normal dose.
Oral: 0.03-0.08 mg/kg/dose every 3-4 hours; Intravenous/Intramuscular: 0.015-0.02 mg/kg/dose every 4-6 hours. Maximum single dose not to exceed 5 mg.
0.1-0.2 mg/kg intravenously or intramuscularly every 4 hours as needed; maximum single dose 15 mg.
Start at 25-50% of adult dose; increase cautiously. For oral, start with 1-2 mg every 4-6 hours. For parenteral, use 0.2-0.5 mg every 4-6 hours. Monitor for respiratory depression and constipation.
Start at 25-50% of the usual adult dose; titrate cautiously; monitor for respiratory depression and constipation.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome (prolonged use in pregnancy); risks with concomitant use of benzodiazepines or other CNS depressants (may cause profound sedation, respiratory depression, coma, death).
Risk of respiratory depression (especially in elderly, cachectic, debilitated); risk of opioid-induced hyperalgesia; risk of hypotension (especially in hypovolemic patients); risk of seizures; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; androgen deficiency; severe hypotension; gastrointestinal obstruction; impaired consciousness; head injury; increased intracranial pressure; acute abdominal conditions; biliary tract disease; acute pancreatitis; use in pregnancy (neonatal withdrawal); breastfeeding (withdrawal in infant); use with MAOIs; severe renal or hepatic impairment.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to morphine or any component; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Avoid alcohol; increased risk of severe respiratory depression, sedation, and hypotension. Grapefruit juice may increase hydromorphone plasma concentration and risk of adverse effects. High-fat meals may delay absorption of immediate-release formulations slightly but not clinically significant.
Avoid alcohol; may increase CNS depression. Grapefruit juice may theoretically alter morphine metabolism via CYP3A4 inhibition, but clinical significance is minimal; no strict avoidance required. High-fat meals may delay absorption but do not affect overall bioavailability. Maintain adequate fluid and fiber intake to prevent constipation.
Hydromorphone is excreted into breast milk in low concentrations. The M/P ratio is not well established but estimated to be approximately 0.7-1.0. Relative infant dose is less than 2-3% of maternal weight-adjusted dose, considered compatible with breastfeeding. Monitor infant for drowsiness, respiratory depression, and feeding difficulties. Use caution with prolonged therapy.
Morphine is excreted into breast milk. M/P ratio approximately 1.1. In therapeutic doses, amounts are low (<10% of maternal weight-adjusted dose) and unlikely to cause adverse effects in healthy term infants. Caution in preterm infants or those with respiratory compromise.
Pregnancy may increase clearance of hydromorphone due to expanded plasma volume and increased renal blood flow. Effective dose may need to be increased by 20-50% in some patients, but titrate to effect and avoid supratherapeutic doses. Postpartum clearance returns rapidly, requiring dose reduction to pre-pregnancy levels.
Increased renal clearance and plasma volume may require higher doses to achieve analgesia. Consider dose titration based on clinical response. Avoid high doses near term to minimize neonatal respiratory depression. Use lowest effective dose for shortest duration.
Do not crush, chew, or break extended-release tablets; swallow whole.,Do not consume alcohol while taking hydromorphone; may cause fatal overdose.,Avoid driving or operating machinery until you know how this medication affects you.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store securely, out of reach of others; dispose of unused medication via take-back programs.,Report severe drowsiness, slow breathing, or difficulty breathing immediately.,Avoid other CNS depressants (e.g., benzodiazepines, alcohol) without doctor approval.,If you have a history of adrenal insufficiency, report fatigue, weakness, or low blood pressure.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of respiratory depression.,Morphine may cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Constipation is a common side effect; increase fluid and fiber intake, and use a stool softener or laxative as recommended.,Do not stop taking suddenly; withdrawal symptoms may occur. Taper under medical supervision.,Store securely out of reach of children and pets; dispose of unused medication via a take-back program.